Eisai Perampanel approved for 2 new indications

Text | Sunshine

On July 30, the NMPA official website showed that Eisai’s Perampanel was approved for two new indications for the treatment of partial-onset epilepsy in patients with epilepsy ≥ 4 years of age, and as a monotherapy for the treatment of partial-onset epilepsy.
Epilepsy
.

Epilepsy is a chronic brain disease that manifests as recurrent seizures.
Patients have different forms of seizures, and they will suddenly have seizures for no reason.
They can be manifested as convulsions, convulsions, fainting, straight eyes, staring and other clinical symptoms.
It has the characteristics of paroxysmal, transient, repetitive and stereotyped
.

According to statistics, there are about 60 million patients with epilepsy in the world.
In China, there are about 9 million patients with epilepsy.
About 60% of patients are affected by partial-onset epilepsy.
About 30% of epilepsy patients cannot use existing anti-epileptic drugs.
Control the condition
.

Perampanel is a highly selective, non-competitive AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, which can inhibit synapses by targeting The glutamate activity of the posterior membrane AMPA receptor reduces the overexcitement of neurons associated with seizures
.

Perampanel structure

The medical cube database NextPharma shows that the currently approved indications for perampanel are: 1) focal epileptic seizures; 2) epileptic generalized tonic-clonic seizures
.

According to Eisai's annual report, since the launch of Perampanel in 2012, its sales have increased year by year
.

In September 2019, Perampanel was approved for marketing in China for the add-on treatment of patients with partial epilepsy (with or without secondary generalized seizures) aged 12 years and older
.